International Myeloma Foundation

MYELOMA MINUTE | Up To The Minute News | 8.25.2022

Do You Know Myeloma? September is Blood Cancer Awareness Month

This Blood Cancer Awareness Month, the International Myeloma Foundation (IMF) is bringing multiple myeloma to the forefront through its #kNOwMyeloma campaign.  The IMF aims to increase awareness of the second most common blood cancer in the world, while engaging with the myeloma community to inspire them to continue advocating for those impacted by the disease. Throughout the month of September, the IMF will ask one simple question: “Do You Know Myeloma?” The IMF’s Blood Cancer Awareness website contains a rich trove of shareable myeloma facts, research breakthroughs in myeloma treatment, and inspirational stories of hope and resilience from those living with the disease. To learn more, visit knowmyeloma.org.

Share on Facebook Share on Twitter LinkedIn

Last Call for Applications: The 2023 Brian D. Novis Research Grants

Only a few days left to apply for the 2023 Brian D. Novis Research (BDN) Grants! Established in 1995 to honor IMF co-founder Brian D. Novis, who succumbed to multiple myeloma in July 1992, BDN Research Grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. Deadline for submission of applications is September 1, 2022.

Share on FacebookShare on TwitterLinkedIn

Download the BLENREP® (belantamab mafodotin-blmf) Tip Card—2022 Edition 

Blenrep® (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen (BCMA), coupled with monomethyl auristatin F (MMAF), a drug that can kill myeloma cells. Get your FREE copy of the IMF’s BLENREP® (belantamab mafodotin-blmf) Tip Card in printed form or as a downloadable PDF with hyperlinks to informative resources.

Share on Facebook Share on Twitter LinkedIn

Watch the Replay: IMF PFW—Back to Basics: From Testing to Tailored Therapy

The IMF Patient & Family Webinar (PFW) – Back to Basics: From Testing to Tailored Therapy was held on Saturday, August 20. Topics discussed include Recommended Testing and Monitoring: 2022 Algorithms, Frontline Options, Managing Myeloma Care, and Relapse Options: FDA Approved/Clinical Trials. In case you missed it, you can still watch the replay.

Share on Facebook Share on Twitter LinkedIn

August is National Make-a-Will Month

Get started today by using this free online resource to create your will and protect what matters most – while creating a legacy with the International Myeloma Foundation (IMF). 

Share on Facebook Share on Twitter LinkedIn

Andy Sninsky Fundraiser: Riding Towards a Cure

14-year myeloma survivor Andy Sninsky has once again embarked on his 1,000+ mile bike ride to raise funds for myeloma research. “My goal on these bicycle adventures is to be inspired, as well as to inspire other patients not to give up. If you have a desire to help patients to feel well then, the support you give here will go to research in search of a cure,” says Andy. Will you support Andy's goal of raising $5,000?

Share on FacebookShare on TwitterLinkedIn

4th Annual Inland Empire/Virtual/In Person Walk for Myeloma Miracles 

The 4th Annual Inland Empire/Virtual/In Person Walk for Myeloma Miracles will be held on Saturday, September 24, 9:00 a.m. PST at Central Park in Rancho Cucamonga, CA. You may register as a participant or a team member, donate to a participant or a team, or purchase a Remembrance Path. Donations will also be accepted on the day of the event. Everyone is encouraged to run, walk, bike, or treadmill their own path to complete the Virtual Walk/In Person for Myeloma Miracles. For more information or to register, visit https://fundraising.myeloma.org/myeloma-miracles.

Share on Facebook Share on Twitter LinkedIn

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

Are myeloma patients being cured when treated early and aggressively?

Share on FacebookShare on TwitterLinkedIn

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

 

Upcoming Events

Donate Now
Pieces to A Cure Quilt Raffle

Donate Now
9th Annual Guys and Gears Car Show

Donate Now
Creatives Against Cancer

Webinar Replays

Watch the Replay
Regional Community Workshop — East South Central

Watch the Replay
2nd Virtual M-Power Charlotte Webinar

Watch the Replay
Living Well with Myeloma — A Promising Future for Treating MM with Bispecific Antibodies

See also, all of our events.

We Thank Our Sponsors:

Bristol Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics,
Legend Biotech, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

We also thank individuals like you for your continued support!
Subscribe
Donate

Join the conversation at The International Myeloma Foundation

Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy

View as web page